Navigation Links
China Cord Blood Corporation Reports Financial Results for the Second Quarter and First Half of Fiscal 2013
Date:11/19/2012

HONG KONG, Nov. 19, 2012 /PRNewswire-FirstCall/ -- China Cord Blood Corporation (NYSE: CO) ("CCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced its preliminary unaudited financial results for the second quarter and first half of fiscal year 2013, which ended September 30, 2012.

Second Quarter of Fiscal 2013 Highlights

  • Revenues for the second quarter of fiscal 2013 increased by 30.5% to RMB128.5 million ($20.4 million) from RMB98.4 million in the prior year period.
  • New subscriber sign-ups and accumulated subscriber base were 18,491 and 274,705, respectively.
  • Gross profit increased by 32.3% to RMB101.4 million ($16.1 million) from RMB76.7 million in the prior year period.
  • Gross margin was 78.9%, compared to 77.9% in the prior year period.
  • Operating income increased by 24.7% to RMB47.0 million ($7.5 million) from RMB37.7 million in the prior year period, after taking into account the increased management and staff related costs.
  • Interest expense amounted to RMB14.1 million ($2.2 million), which was largely attributable to the convertible note issued to KKR China Healthcare Investment Limited ("KKR"), compared to RMB1.2 million in the prior year period.
  • Net income attributable to shareholders increased by 6.2% to RMB24.7 million ($3.9 million) from RMB23.2 million in the prior year period.
  • Operating cash flow for the quarter amounted to RMB142.5 million ($22.7 million).
  • First Half of Fiscal 2013 Highlights

  • Revenues for the first half of fiscal 2013 increased by 31.1% to RMB243.8 million ($38.8 million) from RMB185.9 million in the prior year period.
  • New subscriber sign-up reached 34,951 and accumulated subscriber base expanded to 274,705.
  • G
    '/>"/>

  • SOURCE China Cord Blood Corporation
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

    Related biology technology :

    1. China Cord Blood Corporation Announces Completion of Strategic Partnership with Cordlife Group Limited
    2. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2013 Financial Results
    3. China Biologic Products to Report Third Quarter 2012 Financial Results
    4. Life Technologies New State-of-the-Art Manufacturing Facility in China Provides Forensics Labs Rapid Access to World-Leading DNA Testing Solutions
    5. China Cord Blood Corporation and Golden Meditech Holdings Limited Enter into Convertible Note Financing to Further Expand Cord Blood Banking Services
    6. Hawaii Tech Asia Takes Hawaii & US Entrepreneurs To China
    7. Orthobiologics Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018: China Market Research Reports
    8. China Cord Blood Corporation Reports Financial Results for the First Quarter of Fiscal 2013
    9. China Cord Blood Corporation to Report First Quarter of Fiscal 2013 Financial Results
    10. China Cord Blood Corporation and Cordlife Group Limited Foster Closer Alliance Across Asia
    11. China Biologic Reports Financial Results for the Second Quarter and First Half of 2012
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)... Earlier this year in a June 24 international ... Adult Stem Cell Technology Center, LLC ( ASCTC ) ... unique property of adult tissue stem cells. His ... the Past, Important for the Future,” embodied the essence ... the address at the 4th World Congress on Cell ...
    (Date:12/24/2014)... The report provides basic ... definition, classification, application and industry overview. This ... and product cost structure. Production is separated ... also covers upstream raw materials, equipment, downstream ... and proposals. In the end, the export ...
    (Date:12/24/2014)... , Dec. 23, 2014 China Biologic ... "Company"), a leading fully integrated plasma-based biopharmaceutical company ... that its majority-owned subsidiary, Shandong Taibang Biological Products ... certification from the China Food and Drug Administration ... facility. As previously disclosed in the Company,s public ...
    (Date:12/24/2014)... , Dec. 23, 2014  Rock Creek Pharmaceuticals, ... it has filed a Clinical Trial Application (CTA) with ... products Regulatory Agency (MHRA) seeking regulatory approval to initiate ... molecule, Anatabine Citrate. Contingent on the Company ... a Phase I trial to assess the safety, tolerability ...
    Breaking Biology Technology:Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3
    ... Although Madison has made a deal with Georgia-based ... deployment will not be an overnight event. Certain areas will ... around Capitol Square expected to be approved by the City ... the city of Madison has taken an active role in ...
    ... vice president Kevin Conroy is stepping into the shoes of ... and previously held other executive roles at the company, has ... a specific purpose," Puisis said in a statement. "With a ... place, that purpose has been completed." , ,Third Wave is ...
    ... has tripled Third Wave Technologies ' compensation in ... $15.9 million plus legal fees. Stratagene is proceeding with ... after the judge found that Stratagene willfully infringed on ... Third Wave $5.3 million. , ,Third Wave uses the ...
    Cached Biology Technology:Madison wireless deal goes forward with Cellnet 2
    (Date:11/21/2014)... According to a new market research report ... Control, Intrusion Detection, Parking Management, Under Vehicle Inspection), End ... - Global Forecasts to 2020", published by MarketsandMarkets, The ... $25 Billion in 2014 and is expected to reach ... 8.69%. Browse 116 market data Tables and ...
    (Date:11/21/2014)... 20, 2014 C-Labs LLC, a leading provider ... Things (IoT), today announced the appointment of John ... Previously a strategic advisor to the firm, Mr. Traynor ... Traynor is based out of the C-Labs office in ... Chris Muench , Chief Executive Officer. ...
    (Date:11/18/2014)... BOSTON , Nov. 17, 2014   ... HealthCare and EMC collaborate to develop The Partners ... , The Partners Data Lake will allow ... to improve diagnostics, treatment and the lives of ... support research and clinical activities across the Partners ...
    Breaking Biology News(10 mins):Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5
    ... in immune cells may be a reliable marker for ... appearing in the July issue of Molecular and ... and complex psychiatric illness that affects about 1% of ... and the assessment of ambiguous symptoms, which frequently leads ...
    ... JULY 7, 2008 -- The Soil Science Society of ... Sherrod Brown and his colleagues in the Senate who ... "essential" natural resource, placing soil on par with water ... joined by co-sponsoring Senators Kent Conrad (D-ND), Charles Grassley ...
    ... The effective treatment of many forms of cancer continues ... fail to respond to standard forms of chemotherapy or ... Centre for Infection Research (HZI) in Braunschweig, the Hannover ... now discovered a chemical mechanism with which a natural ...
    Cached Biology News:Senate resolution shines spotlight on the importance of soils 2Argyrin: Natural substance raises hope for new cancer therapies 2
    GLP-1 (HYB 147-12)...
    ... Custom Synthesis Service provides you ... to knockdown any gene. We ... base pairs with terminal dT ... other lengths of your choice. ...
    EDG-1 Western blot control Source: Cell Lysate Application: Western Blotting Control...
    Kit containing positive control DNA all parts of the HIV-1 genome, HIV-1 negative control DNA, Primers SK38, SK39, SK19...
    Biology Products: